Barclays’s Cardinal Health CAH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-1,200
Closed -$64K 4723
2020
Q4
$64K Hold
1,200
﹤0.01% 4313
2020
Q3
$56K Hold
1,200
﹤0.01% 4538
2020
Q2
$63K Sell
1,200
-108,500
-99% -$5.59M ﹤0.01% 4815
2020
Q1
$5.26M Sell
109,700
-5,900
-5% -$306K ﹤0.01% 1421
2019
Q4
$5.85M Buy
115,600
+30,100
+35% +$1.55M ﹤0.01% 1847
2019
Q3
$4.04M Sell
85,500
-2,600
-3% -$119K ﹤0.01% 2041
2019
Q2
$4.15M Buy
88,100
+55,800
+173% +$2.57M ﹤0.01% 2046
2019
Q1
$1.55M Sell
32,300
-20,700
-39% -$1.04M ﹤0.01% 2878
2018
Q4
$2.36M Sell
53,000
-10,900
-17% -$568K ﹤0.01% 2239
2018
Q3
$3.45M Buy
63,900
+5,900
+10% +$302K ﹤0.01% 2226
2018
Q2
$2.83M Sell
58,000
-32,900
-36% -$1.87M ﹤0.01% 2238
2018
Q1
$5.7M Buy
90,900
+17,700
+24% +$1.21M ﹤0.01% 1544
2017
Q4
$4.49M Buy
73,200
+49,300
+206% +$3.05M ﹤0.01% 1746
2017
Q3
$1.6M Sell
23,900
-19,800
-45% -$1.4M ﹤0.01% 2557
2017
Q2
$3.4M Buy
43,700
+25,500
+140% +$1.92M ﹤0.01% 1778
2017
Q1
$1.48M Sell
18,200
-5,100
-22% -$401K ﹤0.01% 2363
2016
Q4
$1.68M Sell
23,300
-27,600
-54% -$2M ﹤0.01% 2271
2016
Q3
$3.96M Buy
50,900
+11,200
+28% +$905K ﹤0.01% 1474
2016
Q2
$3.1M Buy
39,700
+26,800
+208% +$2.14M ﹤0.01% 1661
2016
Q1
$1.04M Sell
12,900
-18,300
-59% -$1.49M ﹤0.01% 2475
2015
Q4
$2.78M Buy
31,200
+6,100
+24% +$518K ﹤0.01% 1758
2015
Q3
$1.91M Buy
25,100
+7,500
+43% +$627K ﹤0.01% 2168
2015
Q2
$1.46M Buy
17,600
+4,700
+36% +$415K ﹤0.01% 2516
2015
Q1
$1.16M Sell
12,900
-3,600
-22% -$310K ﹤0.01% 2833
2014
Q4
$1.32M Buy
16,500
+2,800
+20% +$221K ﹤0.01% 2929
2014
Q3
$1.01M Sell
13,700
-800
-6% -$58.2K ﹤0.01% 3338
2014
Q2
$986K Sell
14,500
-4,400
-23% -$300K ﹤0.01% 3350
2014
Q1
$1.3M Sell
18,900
-121,300
-87% -$8.44M ﹤0.01% 2948
2013
Q4
$9.25M Buy
140,200
+73,700
+111% +$4.5M 0.01% 1313
2013
Q3
$3.46M Sell
66,500
-98,300
-60% -$4.99M ﹤0.01% 2021
2013
Q2
$7.78M Buy
+164,800
New +$7.53M 0.01% 1279

Other funds holding CAH

Barclays's CAH Position: Q1 2026 in Review

Barclays reduced its Cardinal Health (CAH) stake by 18% in Q1 2026, selling an estimated $46.2M and leaving 993,914 shares worth $210M. The position accounts for 0.05% of the portfolio, ranked #288.

Barclays first reported a position in CAH in Q2 2013 and has held it in 52 quarters since. The position peaked at $249M in Q3 2025. 1,423 funds tracked by Wall St. Rank hold CAH as of Q1 2026.

  • Barclays held 993,914 shares of Cardinal Health worth $210M as of Q1 2026.
  • Barclays sold 214,685 Cardinal Health shares in Q1 2026, an estimated $46.2M.
  • Cardinal Health made up 0.05% of Barclays's portfolio in Q1 2026, its #288 holding.
  • Barclays first reported a position in Cardinal Health in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Cardinal Health position peaked at $249M in Q3 2025.
  • 1,423 funds tracked by Wall St. Rank held Cardinal Health as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.